Spread the love

FAQs

What causes a virus to change to a new variant?

All viruses – including SARS-CoV-2, the virus that causes Covid-19 – evolve over time. When a virus replicates or makes copies of itself, it sometimes changes a little bit, which is normal for a virus. These changes are called “mutations”. A virus with one or more new mutations is referred to as a “variant” of the original virus.

When a virus is widely circulating in a population and causing many infections, the likelihood of the virus mutating increases. The more opportunities a virus has to spread, the more it replicates – and the more opportunities it has to undergo changes.

Most viral mutations have little to no impact on the virus’s ability to cause infections and disease. But depending on where the changes are located in the virus’s genetic material, they may affect a virus’s properties, such as transmission (for example, it may spread more or less easily) or severity (for example, it may cause more or less severe disease).

What impact do the new variants of the Covid-19 virus have on vaccines?

The Covid-19 vaccines that are currently in development or have been approved are expected to provide at least some protection against new virus variants because these vaccines elicit a broad immune response involving a range of antibodies and cells.

Therefore, changes or mutations in the virus should not make vaccines completely ineffective. In the event that any of these vaccines prove to be less effective against one or more variants, it will be possible to change the composition of the vaccines to protect against these variants.

Data continues to be collected and analysed on new variants of the Covid-19 virus. WHO is working with researchers, health officials and scientists to understand how these variants affect the virus’s behaviour, including their impact on the effectiveness of vaccines, if any.

While we are learning more, we need to do everything possible to stop the spread of the virus in order to prevent mutations that may reduce the efficacy of existing vaccines.

In addition, manufacturers and the programmes using the vaccines may have to adjust to the evolution of the Covid-19 virus: for example, vaccines may need to incorporate more than one strain when in development, booster shots may be required, and other vaccine changes may be needed.

Trials must also be designed and maintained to allow any changes in efficacy to be assessed and must be of sufficient scale and diversity to enable clear interpretation of results. Studies of the impact of vaccines as they are deployed are also essential in order to understand their impact.

Source: World Health Organization (WHO)